文献速递术前评估与围术期医学产科麻醉

舒更葡糖与新斯的明/格隆溴铵逆转神经肌肉阻滞的恢复特征:随机对照试验

Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: a randomised controlled trial.
PubMed 文献 · Anaesthesia · 2017-12-07

主要结局术后6小时恶心呕吐发生率两组无显著差异(49.0% vs 51.0%)。舒更葡糖组复视和口干更少,2小时镇静评分更低。

要点

  • 舒更葡糖未减少术后6小时恶心呕吐发生率
  • 舒更葡糖组复视和口干发生率更低
  • 舒更葡糖组2小时镇静评分更低

核心结论

  • 在该患者群体中,舒更葡糖逆转神经肌肉阻滞未减少术后恶心呕吐。

主要发现

  • 术后6小时恶心呕吐发生率舒更葡糖组49.0% vs 新斯的明组51.0%(OR 0.92,95%CI 0.59-1.45;p=0.731)。
  • 复视发生率11.5% vs 20.0%(p=0.044),口干发生率71.6% vs 85.5%(p=0.003),舒更葡糖组更低。
  • 2小时镇静评分中位数(IQR[范围])舒更葡糖组0(0-3[0-10]) vs 新斯的明组2(0-4[0-10])(p=0.021)。

关键数值与推荐

  • 舒更葡糖剂量2 mg.kg-1,新斯的明40 μg.kg-1联合格隆溴铵400 μg。
  • 主要结局为术后6小时恶心呕吐发生率。

临床怎么用

  • 对于接受日间腹腔镜妇科手术的女性,选择舒更葡糖逆转罗库溴铵阻滞不能预期减少早期术后恶心呕吐。
  • 舒更葡糖可能降低复视、口干和早期镇静程度,但需结合个体情况权衡。

局限性

  • 单中心研究,仅限女性日间腹腔镜妇科手术人群。
  • 分析中包含4例重大方案违背。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sugammadex more rapidly and reliably reverses rocuronium-induced neuromuscular block compared with neostigmine, but it is not known if subsequent patient outcomes, including nausea, vomiting and other aspects of recovery are modified. In this study, we compared the recovery characteristics of sugammadex and neostigmine/glycopyrrolate following reversal of neuromuscular block. This was a single-centre, randomised, blinded, parallel-group clinical trial in women undergoing elective day-surgical laparoscopic gynaecological surgery, with a standardised general anaesthesia regimen that included rocuronium. Neuromuscular block was reversed with either sugammadex 2 mg.kg-1 or neostigmine 40 μg.kg-1 and glycopyrrolate 400 μg. The primary outcome was the incidence of nausea and vomiting during the first six postoperative hours. Secondary outcomes included other measures of postoperative recovery such as patient symptoms and recovery scores. Three-hundred and four women were analysed by intention-to-treat (sugammadex n = 151, neostigmine n = 153), which included four major protocol violations. There was no significant difference between sugammadex and neostigmine groups in the incidence of early nausea and vomiting (49.0% vs. 51.0%, respectively; OR 0.92, 95%CI 0.59-1.45; p = 0.731). Double vision (11.5% vs. 20.0%; p = 0.044) and dry mouth (71.6% vs. 85.5%; p = 0.003) were less common after sugammadex. Sedation scores at 2 h were also lower after sugammadex (median (IQR [range]) 0 (0-3 [0-10]) vs. 2 (0-4.[0-10]); p = 0.021). Twenty-four-hour recovery scores were not significantly different between groups. Reversal with sugammadex in this patient population did not reduce postoperative nausea or vomiting compared with neostigmine/glycopyrrolate.

来源:Anaesthesia,查看原文。版权归原作者所有。

引用

  1. Paech MJ, Kaye R, Baber C, et al. Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: a randomised controlled trial. Anaesthesia. 2017. PMID: 29214645. doi:10.1111/anae.14174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。